1. Home
  2. SUPN
  3. SUPN News

Latest Supernus Pharmaceuticals Inc. (SUPN) News on April 19, 2025

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth?
SUPN

Insider Monkey

2 days ago

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth?

SUPN

Argus Research

4 days ago

SUPN: Raising target price to $33.00

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
SUPN

StockStory

9 days ago

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks

SUPN

Argus Research

11 days ago

SUPN: Lowering target price to $32.00

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
SUPN

StockStory

11 days ago

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?
SUPN

StockStory

15 days ago

Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
SUPN

StockStory

17 days ago

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

SUPN

Argus Research

18 days ago

SUPN: Lowering target price to $33.00

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
SUPN

StockStory

23 days ago

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

SUPN

Argus Research

25 days ago

SUPN: Raising target price to $35.00

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.
SUPN

Investor's Business Daily

25 days ago

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
SUPN

StockStory

a month ago

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround
SUPN

Zacks

a month ago

Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
SUPN

StockStory

a month ago

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

3 Small-Cap Stocks Skating on Thin Ice
SUPN

StockStory

a month ago

3 Small-Cap Stocks Skating on Thin Ice

Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts
SUPN

Insider Monkey

a month ago

Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

SUPN

Argus Research

2 months ago

SUPN: Lowering target price to $33.00

Supernus to Participate in Two Upcoming Investor Conferences
SUPN

GlobeNewswire

2 months ago

Supernus to Participate in Two Upcoming Investor Conferences

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
SUPN

StockStory

2 months ago

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
SUPN

StockStory

2 months ago

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?
SUPN

Simply Wall St.

2 months ago

Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?
SUPN

Insider Monkey

2 months ago

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
SUPN

GlobeNewswire

2 months ago

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

SUPN

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Supernus Pharmaceuticals Inc Earnings Call

SUPN

MT Newswires

2 months ago

Supernus Pharmaceuticals Q4 Earnings, Revenue Rise; Provides 2025 Revenue Guidance

Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
SUPN

GuruFocus.com

2 months ago

Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

SUPN

Argus Research

2 months ago

SUPN: Lowering target price to $34.00

Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
SUPN

Zacks

2 months ago

Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
SUPN

Zacks

2 months ago

Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
SUPN

StockStory

2 months ago

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers

SUPN

Associated Press Finance

2 months ago

Supernus: Q4 Earnings Snapshot

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
SUPN

GlobeNewswire

2 months ago

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
SUPN

StockStory

2 months ago

What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
SUPN

Benzinga

2 months ago

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

SUPN

MT Newswires

2 months ago

Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57

SUPN

MT Newswires

2 months ago

Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint

SUPN

Argus Research

2 months ago

SUPN: Raising target price to $42.00

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
SUPN

GlobeNewswire

2 months ago

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
SUPN

GlobeNewswire

2 months ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
SUPN

Zacks

2 months ago

Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade

Supernus wins FDA approval for Parkinson’s pump on fourth try
SUPN

Pharmaceutical Technology

2 months ago

Supernus wins FDA approval for Parkinson’s pump on fourth try

SUPN

Argus Research

2 months ago

SUPN: Raising target price to $42.00

SUPN

MT Newswires

2 months ago

Supernus Pharmaceuticals Says Onapgo Approved by FDA for Parkinson's Disease

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
SUPN

GlobeNewswire

2 months ago

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

7MM PD market to grow by $4.5bn between 2023 and 2033
SUPN

Clinical Trials Arena

3 months ago

7MM PD market to grow by $4.5bn between 2023 and 2033

SUPN

Argus Research

3 months ago

SUPN: What does Argus have to say about SUPN?

SUPN

MT Newswires

3 months ago

Supernus Pharmaceuticals Says US FDA Approves Label Update for ADHD Treatment Qelbree

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
SUPN

GlobeNewswire

3 months ago

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

SUPN

Argus Research

3 months ago

SUPN: Raising target price to $41.00

SUPN

Argus Research

3 months ago

SUPN: Raising target price to $40.00

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years
SUPN

Simply Wall St.

3 months ago

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years

SUPN

MT Newswires

3 months ago

Cantor Fitzgerald Initiates Supernus Pharmaceuticals at Overweight With $57 Price Target

SUPN

Argus Research

4 months ago

SUPN: Lowering target price to $39.00

SUPN

Argus Research

4 months ago

SUPN: Rating increased to a BUY

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada
SUPN

GlobeNewswire

4 months ago

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

SUPN

Argus Research

4 months ago

SUPN: What does Argus have to say about SUPN?

SUPN

Argus Research

5 months ago

SUPN: Raising target price to $39.00

SUPN

Argus Research

5 months ago

SUPN: Raising target price to $38.00

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
SUPN

GlobeNewswire

5 months ago

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
SUPN

GlobeNewswire

5 months ago

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

SUPN

Argus Research

5 months ago

SUPN: Raising target price to $40.00

SUPN

MT Newswires

5 months ago

Supernus Pharmaceuticals Insider Sold Shares Worth $4,536,250, According to a Recent SEC Filing

SUPN

MT Newswires

5 months ago

Supernus Pharmaceuticals Insider Sold Shares Worth $391,568, According to a Recent SEC Filing

SUPN

MT Newswires

5 months ago

Supernus Pharmaceuticals Insider Sold Shares Worth $520,480, According to a Recent SEC Filing

Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
SUPN

Simply Wall St.

5 months ago

Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

SUPN

Argus Research

5 months ago

SUPN: What does Argus have to say about SUPN?

Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
SUPN

GuruFocus.com

5 months ago

Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

SUPN

MT Newswires

5 months ago

Supernus Pharmaceuticals Q3 Swings to Profit, Revenue Increases; 2024 Revenue Outlook Lifted

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
SUPN

Zacks

5 months ago

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
SUPN

Zacks

5 months ago

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

SUPN

Associated Press Finance

5 months ago

Supernus: Q3 Earnings Snapshot

Supernus Announces Third Quarter 2024 Financial Results
SUPN

GlobeNewswire

5 months ago

Supernus Announces Third Quarter 2024 Financial Results

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
SUPN

GlobeNewswire

6 months ago

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
SUPN

GlobeNewswire

6 months ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

Supernus’ depression drug improved symptoms in two hours in Phase IIa study
SUPN

Clinical Trials Arena

6 months ago

Supernus’ depression drug improved symptoms in two hours in Phase IIa study

SUPN

MT Newswires

6 months ago

Supernus Pharmaceuticals Reports 'Promising' Data in Trial of Anti-Depression Drug Candidate

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
SUPN

GlobeNewswire

6 months ago

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
SUPN

GlobeNewswire

6 months ago

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
SUPN

GuruFocus.com

6 months ago

Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

SUPN

Argus Research

6 months ago

SUPN: What does Argus have to say about SUPN?

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
SUPN

GlobeNewswire

7 months ago

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
SUPN

Simply Wall St.

7 months ago

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
SUPN

GlobeNewswire

7 months ago

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug
SUPN

Insider Monkey

7 months ago

Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
SUPN

Benzinga

7 months ago

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
SUPN

GlobeNewswire

8 months ago

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

SUPN

Argus Research

8 months ago

SUPN: What does Argus have to say about SUPN?

SUPN

Argus Research

8 months ago

SUPN: Raising target price to $28.00

SUPN

MT Newswires

8 months ago

Supernus Pharmaceuticals Says US FDA Accepts NDA Resubmission for Potential Parkinson's Related Treatment Device

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
SUPN

GlobeNewswire

8 months ago

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Some May Be Optimistic About Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings
SUPN

Simply Wall St.

8 months ago

Some May Be Optimistic About Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
SUPN

Zacks

8 months ago

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?

Supernus Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
SUPN

Simply Wall St.

8 months ago

Supernus Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
SUPN

Zacks

8 months ago

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
SUPN

Zacks

8 months ago

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

SUPN

Associated Press Finance

8 months ago

Supernus: Q2 Earnings Snapshot

Supernus Announces Second Quarter 2024 Financial Results
SUPN

GlobeNewswire

8 months ago

Supernus Announces Second Quarter 2024 Financial Results

SUPN

MT Newswires

9 months ago

Supernus Pharmaceuticals Resubmits Marketing Application for Parkinson's Treatment Device

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
SUPN

GlobeNewswire

9 months ago

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

Those who invested in Supernus Pharmaceuticals (NASDAQ:SUPN) three years ago are up 13%
SUPN

Simply Wall St.

9 months ago

Those who invested in Supernus Pharmaceuticals (NASDAQ:SUPN) three years ago are up 13%

Share on Social Networks: